Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Swine Mycoplasma Hyopneumoniae Live Vaccine market size was valued at US$ 29.63 million in 2025 and is forecast to a readjusted size of US$ 41.94 million by 2032 with a CAGR of 5.0% during review period.
Swine Mycoplasma Hyopneumoniae Live Vaccine is a preventive veterinary biological product formulated with live attenuated Mycoplasma hyopneumoniae strains, mainly used for the prevention of swine enzootic pneumonia, mycoplasmal pneumonia and related respiratory diseases in pigs. Commercial products are generally supplied as freeze-dried live vaccines, and the currently verifiable mainstream strain routes mainly include Strain 168 and Strain RM48, with administration routes such as intrapulmonary injection, intrathoracic injection and intranasal inoculation depending on product design. Upstream inputs mainly include production seed strains, specialized culture media, serum or serum substitutes, lyoprotectants, stabilizers, cultivation and harvesting consumables, vials or plastic bottles, rubber stoppers, aluminum caps, labels, cold-chain packaging materials and GMP-compliant biological manufacturing facilities. Downstream customers primarily include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease prevention service providers and field veterinary service channels. Under a strict live-vaccine ex-factory scope, global effective production capacity in 2025 is estimated at about 218 million doses, with sales volume of about 151 million doses and an average ex-factory price of about USD 0.19 per dose. As commercialized supply is mainly concentrated in China, mainstream overseas Mycoplasma hyopneumoniae vaccines that are inactivated vaccines or combination vaccines are not included in this statistical scope. The industry gross margin in 2025 is estimated at around 45%–60%.
The current market is mainly centered on domestic production and application in China, and it remains a specialized segment within the veterinary vaccine industry. Supply is relatively concentrated, and demand mainly comes from large-scale pig farms, breeding farms and production systems with higher requirements for respiratory disease control. Compared with conventional inactivated vaccines, live vaccines place greater emphasis on respiratory local immunity and integrated herd-level disease prevention, giving them a stable application base in selected high-health-status farms.
Future development will focus more on administration convenience, product stability and adaptability to large-scale farming operations. As farming enterprises continue to pursue standardized vaccination programs, lower handling stress, reduced labor intensity and more consistent immune outcomes, products with easier administration, better field usability and stronger freeze-dried stability are expected to gain greater acceptance. Competition will increasingly depend on strain resources, manufacturing quality, field application evidence, technical service capability and farm-level solution design.
Market growth is mainly driven by the continued expansion of large-scale pig farming, stronger demand for integrated respiratory disease control, reduced antibiotic use and greater attention to production efficiency. Mycoplasma hyopneumoniae infection can interact with other pathogens and affect herd performance through coughing, lung lesions, slower growth and weaker feed conversion efficiency, so preventive vaccination remains an important part of stable pig production. When farm profitability improves and disease-control budgets recover, the penetration of this product category is expected to increase.
The main restraints include competition from substitute products, higher requirements for standardized use, hog cycle volatility and cost pressure at the farm level. Inactivated vaccines and combination vaccines have strong advantages in program integration, ease of use and channel coverage, so some farms may prefer simpler integrated immunization solutions. In addition, live vaccines require stricter cold-chain storage, reconstitution and administration practices, and improper execution may affect immune performance and repeat purchasing; during periods of weak hog prices, non-mandatory vaccine spending is also more likely to be reduced.
This report is a detailed and comprehensive analysis for global Swine Mycoplasma Hyopneumoniae Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Swine Mycoplasma Hyopneumoniae Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Swine Mycoplasma Hyopneumoniae Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Swine Mycoplasma Hyopneumoniae Live Vaccine, with price, sales quantity, revenue, and global market share of Swine Mycoplasma Hyopneumoniae Live Vaccine from 2021 to 2026.
Chapter 3, the Swine Mycoplasma Hyopneumoniae Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Swine Mycoplasma Hyopneumoniae Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Swine Mycoplasma Hyopneumoniae Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Swine Mycoplasma Hyopneumoniae Live Vaccine.
Chapter 14 and 15, to describe Swine Mycoplasma Hyopneumoniae Live Vaccine sales channel, distributors, customers, research findings and conclusion.
Swine Mycoplasma Hyopneumoniae Live Vaccine is a preventive veterinary biological product formulated with live attenuated Mycoplasma hyopneumoniae strains, mainly used for the prevention of swine enzootic pneumonia, mycoplasmal pneumonia and related respiratory diseases in pigs. Commercial products are generally supplied as freeze-dried live vaccines, and the currently verifiable mainstream strain routes mainly include Strain 168 and Strain RM48, with administration routes such as intrapulmonary injection, intrathoracic injection and intranasal inoculation depending on product design. Upstream inputs mainly include production seed strains, specialized culture media, serum or serum substitutes, lyoprotectants, stabilizers, cultivation and harvesting consumables, vials or plastic bottles, rubber stoppers, aluminum caps, labels, cold-chain packaging materials and GMP-compliant biological manufacturing facilities. Downstream customers primarily include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease prevention service providers and field veterinary service channels. Under a strict live-vaccine ex-factory scope, global effective production capacity in 2025 is estimated at about 218 million doses, with sales volume of about 151 million doses and an average ex-factory price of about USD 0.19 per dose. As commercialized supply is mainly concentrated in China, mainstream overseas Mycoplasma hyopneumoniae vaccines that are inactivated vaccines or combination vaccines are not included in this statistical scope. The industry gross margin in 2025 is estimated at around 45%–60%.
The current market is mainly centered on domestic production and application in China, and it remains a specialized segment within the veterinary vaccine industry. Supply is relatively concentrated, and demand mainly comes from large-scale pig farms, breeding farms and production systems with higher requirements for respiratory disease control. Compared with conventional inactivated vaccines, live vaccines place greater emphasis on respiratory local immunity and integrated herd-level disease prevention, giving them a stable application base in selected high-health-status farms.
Future development will focus more on administration convenience, product stability and adaptability to large-scale farming operations. As farming enterprises continue to pursue standardized vaccination programs, lower handling stress, reduced labor intensity and more consistent immune outcomes, products with easier administration, better field usability and stronger freeze-dried stability are expected to gain greater acceptance. Competition will increasingly depend on strain resources, manufacturing quality, field application evidence, technical service capability and farm-level solution design.
Market growth is mainly driven by the continued expansion of large-scale pig farming, stronger demand for integrated respiratory disease control, reduced antibiotic use and greater attention to production efficiency. Mycoplasma hyopneumoniae infection can interact with other pathogens and affect herd performance through coughing, lung lesions, slower growth and weaker feed conversion efficiency, so preventive vaccination remains an important part of stable pig production. When farm profitability improves and disease-control budgets recover, the penetration of this product category is expected to increase.
The main restraints include competition from substitute products, higher requirements for standardized use, hog cycle volatility and cost pressure at the farm level. Inactivated vaccines and combination vaccines have strong advantages in program integration, ease of use and channel coverage, so some farms may prefer simpler integrated immunization solutions. In addition, live vaccines require stricter cold-chain storage, reconstitution and administration practices, and improper execution may affect immune performance and repeat purchasing; during periods of weak hog prices, non-mandatory vaccine spending is also more likely to be reduced.
This report is a detailed and comprehensive analysis for global Swine Mycoplasma Hyopneumoniae Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Swine Mycoplasma Hyopneumoniae Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Swine Mycoplasma Hyopneumoniae Live Vaccine
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Swine Mycoplasma Hyopneumoniae Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Strain 168 Live Vaccine
- Strain RM48 Live Vaccine
- Others
- Intrapulmonary Injection
- Intrathoracic Injection
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20–50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Pig Farming Groups
- Breeding Pig Farms
- Animal Health Service Providers
- Others
- Jofunhwa Group
- Qianyuanhao Biological
- Jilin Zhengye Biological Products
- Qilu Animal Health Products
- Shandong Lvdu Biotechnology
- Guangdong Wens Dahuanong Biotechnology
- Guangdong Winsun Bio-Pharmaceutical
- Harbin Pharmaceutical Group Bio-vaccine
- Wuhan Zhongbo Biotech
- China Animal Husbandry Industry
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Swine Mycoplasma Hyopneumoniae Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Swine Mycoplasma Hyopneumoniae Live Vaccine, with price, sales quantity, revenue, and global market share of Swine Mycoplasma Hyopneumoniae Live Vaccine from 2021 to 2026.
Chapter 3, the Swine Mycoplasma Hyopneumoniae Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Swine Mycoplasma Hyopneumoniae Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Swine Mycoplasma Hyopneumoniae Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Swine Mycoplasma Hyopneumoniae Live Vaccine.
Chapter 14 and 15, to describe Swine Mycoplasma Hyopneumoniae Live Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Strain 168 Live Vaccine
1.3.3 Strain RM48 Live Vaccine
1.3.4 Others
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Intrapulmonary Injection
1.4.3 Intrathoracic Injection
1.4.4 Others
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Pig Farming Groups
1.6.3 Breeding Pig Farms
1.6.4 Animal Health Service Providers
1.6.5 Others
1.7 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size & Forecast
1.7.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (2021-2032)
1.7.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Jofunhwa Group
2.1.1 Jofunhwa Group Details
2.1.2 Jofunhwa Group Major Business
2.1.3 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.1.4 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Jofunhwa Group Recent Developments/Updates
2.2 Qianyuanhao Biological
2.2.1 Qianyuanhao Biological Details
2.2.2 Qianyuanhao Biological Major Business
2.2.3 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.2.4 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Qianyuanhao Biological Recent Developments/Updates
2.3 Jilin Zhengye Biological Products
2.3.1 Jilin Zhengye Biological Products Details
2.3.2 Jilin Zhengye Biological Products Major Business
2.3.3 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.3.4 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Jilin Zhengye Biological Products Recent Developments/Updates
2.4 Qilu Animal Health Products
2.4.1 Qilu Animal Health Products Details
2.4.2 Qilu Animal Health Products Major Business
2.4.3 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.4.4 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Qilu Animal Health Products Recent Developments/Updates
2.5 Shandong Lvdu Biotechnology
2.5.1 Shandong Lvdu Biotechnology Details
2.5.2 Shandong Lvdu Biotechnology Major Business
2.5.3 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.5.4 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Shandong Lvdu Biotechnology Recent Developments/Updates
2.6 Guangdong Wens Dahuanong Biotechnology
2.6.1 Guangdong Wens Dahuanong Biotechnology Details
2.6.2 Guangdong Wens Dahuanong Biotechnology Major Business
2.6.3 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.6.4 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Guangdong Wens Dahuanong Biotechnology Recent Developments/Updates
2.7 Guangdong Winsun Bio-Pharmaceutical
2.7.1 Guangdong Winsun Bio-Pharmaceutical Details
2.7.2 Guangdong Winsun Bio-Pharmaceutical Major Business
2.7.3 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.7.4 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Guangdong Winsun Bio-Pharmaceutical Recent Developments/Updates
2.8 Harbin Pharmaceutical Group Bio-vaccine
2.8.1 Harbin Pharmaceutical Group Bio-vaccine Details
2.8.2 Harbin Pharmaceutical Group Bio-vaccine Major Business
2.8.3 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.8.4 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Harbin Pharmaceutical Group Bio-vaccine Recent Developments/Updates
2.9 Wuhan Zhongbo Biotech
2.9.1 Wuhan Zhongbo Biotech Details
2.9.2 Wuhan Zhongbo Biotech Major Business
2.9.3 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.9.4 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Wuhan Zhongbo Biotech Recent Developments/Updates
2.10 China Animal Husbandry Industry
2.10.1 China Animal Husbandry Industry Details
2.10.2 China Animal Husbandry Industry Major Business
2.10.3 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.10.4 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 China Animal Husbandry Industry Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY MANUFACTURER
3.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Swine Mycoplasma Hyopneumoniae Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer Market Share in 2025
3.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Overall Company Footprint Analysis
3.5.1 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Region Footprint
3.5.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Type Footprint
3.5.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Region
4.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2021-2032)
4.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.5 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2021-2032)
5.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2021-2032)
6.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
7.3.1 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
8.3.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Region
9.3.1 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
10.3.1 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
11.3.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Swine Mycoplasma Hyopneumoniae Live Vaccine Market Drivers
12.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Market Restraints
12.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Swine Mycoplasma Hyopneumoniae Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Swine Mycoplasma Hyopneumoniae Live Vaccine
13.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Distributors
14.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Strain 168 Live Vaccine
1.3.3 Strain RM48 Live Vaccine
1.3.4 Others
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Intrapulmonary Injection
1.4.3 Intrathoracic Injection
1.4.4 Others
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Pig Farming Groups
1.6.3 Breeding Pig Farms
1.6.4 Animal Health Service Providers
1.6.5 Others
1.7 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size & Forecast
1.7.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (2021-2032)
1.7.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Jofunhwa Group
2.1.1 Jofunhwa Group Details
2.1.2 Jofunhwa Group Major Business
2.1.3 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.1.4 Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Jofunhwa Group Recent Developments/Updates
2.2 Qianyuanhao Biological
2.2.1 Qianyuanhao Biological Details
2.2.2 Qianyuanhao Biological Major Business
2.2.3 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.2.4 Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Qianyuanhao Biological Recent Developments/Updates
2.3 Jilin Zhengye Biological Products
2.3.1 Jilin Zhengye Biological Products Details
2.3.2 Jilin Zhengye Biological Products Major Business
2.3.3 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.3.4 Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Jilin Zhengye Biological Products Recent Developments/Updates
2.4 Qilu Animal Health Products
2.4.1 Qilu Animal Health Products Details
2.4.2 Qilu Animal Health Products Major Business
2.4.3 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.4.4 Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Qilu Animal Health Products Recent Developments/Updates
2.5 Shandong Lvdu Biotechnology
2.5.1 Shandong Lvdu Biotechnology Details
2.5.2 Shandong Lvdu Biotechnology Major Business
2.5.3 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.5.4 Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Shandong Lvdu Biotechnology Recent Developments/Updates
2.6 Guangdong Wens Dahuanong Biotechnology
2.6.1 Guangdong Wens Dahuanong Biotechnology Details
2.6.2 Guangdong Wens Dahuanong Biotechnology Major Business
2.6.3 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.6.4 Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Guangdong Wens Dahuanong Biotechnology Recent Developments/Updates
2.7 Guangdong Winsun Bio-Pharmaceutical
2.7.1 Guangdong Winsun Bio-Pharmaceutical Details
2.7.2 Guangdong Winsun Bio-Pharmaceutical Major Business
2.7.3 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.7.4 Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Guangdong Winsun Bio-Pharmaceutical Recent Developments/Updates
2.8 Harbin Pharmaceutical Group Bio-vaccine
2.8.1 Harbin Pharmaceutical Group Bio-vaccine Details
2.8.2 Harbin Pharmaceutical Group Bio-vaccine Major Business
2.8.3 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.8.4 Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Harbin Pharmaceutical Group Bio-vaccine Recent Developments/Updates
2.9 Wuhan Zhongbo Biotech
2.9.1 Wuhan Zhongbo Biotech Details
2.9.2 Wuhan Zhongbo Biotech Major Business
2.9.3 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.9.4 Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Wuhan Zhongbo Biotech Recent Developments/Updates
2.10 China Animal Husbandry Industry
2.10.1 China Animal Husbandry Industry Details
2.10.2 China Animal Husbandry Industry Major Business
2.10.3 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
2.10.4 China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 China Animal Husbandry Industry Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SWINE MYCOPLASMA HYOPNEUMONIAE LIVE VACCINE BY MANUFACTURER
3.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Swine Mycoplasma Hyopneumoniae Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer Market Share in 2025
3.5 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Overall Company Footprint Analysis
3.5.1 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Region Footprint
3.5.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Type Footprint
3.5.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Region
4.1.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2021-2032)
4.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.5 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2021-2032)
5.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2021-2032)
6.3 Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
7.3.1 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
8.3.1 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Region
9.3.1 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
10.3.1 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Market Size by Country
11.3.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Swine Mycoplasma Hyopneumoniae Live Vaccine Market Drivers
12.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Market Restraints
12.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Swine Mycoplasma Hyopneumoniae Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Swine Mycoplasma Hyopneumoniae Live Vaccine
13.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Distributors
14.3 Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Jofunhwa Group Basic Information, Manufacturing Base and Competitors
Table 6. Jofunhwa Group Major Business
Table 7. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 8. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Jofunhwa Group Recent Developments/Updates
Table 10. Qianyuanhao Biological Basic Information, Manufacturing Base and Competitors
Table 11. Qianyuanhao Biological Major Business
Table 12. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 13. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Qianyuanhao Biological Recent Developments/Updates
Table 15. Jilin Zhengye Biological Products Basic Information, Manufacturing Base and Competitors
Table 16. Jilin Zhengye Biological Products Major Business
Table 17. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 18. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Jilin Zhengye Biological Products Recent Developments/Updates
Table 20. Qilu Animal Health Products Basic Information, Manufacturing Base and Competitors
Table 21. Qilu Animal Health Products Major Business
Table 22. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 23. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Qilu Animal Health Products Recent Developments/Updates
Table 25. Shandong Lvdu Biotechnology Basic Information, Manufacturing Base and Competitors
Table 26. Shandong Lvdu Biotechnology Major Business
Table 27. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 28. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Shandong Lvdu Biotechnology Recent Developments/Updates
Table 30. Guangdong Wens Dahuanong Biotechnology Basic Information, Manufacturing Base and Competitors
Table 31. Guangdong Wens Dahuanong Biotechnology Major Business
Table 32. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 33. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Guangdong Wens Dahuanong Biotechnology Recent Developments/Updates
Table 35. Guangdong Winsun Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guangdong Winsun Bio-Pharmaceutical Major Business
Table 37. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 38. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Guangdong Winsun Bio-Pharmaceutical Recent Developments/Updates
Table 40. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Manufacturing Base and Competitors
Table 41. Harbin Pharmaceutical Group Bio-vaccine Major Business
Table 42. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 43. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Harbin Pharmaceutical Group Bio-vaccine Recent Developments/Updates
Table 45. Wuhan Zhongbo Biotech Basic Information, Manufacturing Base and Competitors
Table 46. Wuhan Zhongbo Biotech Major Business
Table 47. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 48. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Wuhan Zhongbo Biotech Recent Developments/Updates
Table 50. China Animal Husbandry Industry Basic Information, Manufacturing Base and Competitors
Table 51. China Animal Husbandry Industry Major Business
Table 52. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 53. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. China Animal Husbandry Industry Recent Developments/Updates
Table 55. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 56. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 57. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 58. Market Position of Manufacturers in Swine Mycoplasma Hyopneumoniae Live Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 59. Head Office and Swine Mycoplasma Hyopneumoniae Live Vaccine Production Site of Key Manufacturer
Table 60. Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Type Footprint
Table 61. Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Application Footprint
Table 62. Swine Mycoplasma Hyopneumoniae Live Vaccine New Market Entrants and Barriers to Market Entry
Table 63. Swine Mycoplasma Hyopneumoniae Live Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 65. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 66. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 67. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 68. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 69. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 70. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 71. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 72. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 73. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 74. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 75. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 77. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 78. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 79. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 80. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 81. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 82. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 83. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 84. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 85. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 86. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 87. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 88. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 89. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 90. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 91. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 94. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 95. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 96. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 97. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 98. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 99. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 100. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 101. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 102. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 103. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 104. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 105. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 106. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 107. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 108. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 109. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 110. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 111. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 112. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 113. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 114. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 116. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 117. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 118. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 119. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 120. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 121. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 122. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 123. Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Material
Table 124. Key Manufacturers of Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Materials
Table 125. Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Distributors
Table 126. Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Customers
Table 1. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Jofunhwa Group Basic Information, Manufacturing Base and Competitors
Table 6. Jofunhwa Group Major Business
Table 7. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 8. Jofunhwa Group Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Jofunhwa Group Recent Developments/Updates
Table 10. Qianyuanhao Biological Basic Information, Manufacturing Base and Competitors
Table 11. Qianyuanhao Biological Major Business
Table 12. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 13. Qianyuanhao Biological Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Qianyuanhao Biological Recent Developments/Updates
Table 15. Jilin Zhengye Biological Products Basic Information, Manufacturing Base and Competitors
Table 16. Jilin Zhengye Biological Products Major Business
Table 17. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 18. Jilin Zhengye Biological Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Jilin Zhengye Biological Products Recent Developments/Updates
Table 20. Qilu Animal Health Products Basic Information, Manufacturing Base and Competitors
Table 21. Qilu Animal Health Products Major Business
Table 22. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 23. Qilu Animal Health Products Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Qilu Animal Health Products Recent Developments/Updates
Table 25. Shandong Lvdu Biotechnology Basic Information, Manufacturing Base and Competitors
Table 26. Shandong Lvdu Biotechnology Major Business
Table 27. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 28. Shandong Lvdu Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Shandong Lvdu Biotechnology Recent Developments/Updates
Table 30. Guangdong Wens Dahuanong Biotechnology Basic Information, Manufacturing Base and Competitors
Table 31. Guangdong Wens Dahuanong Biotechnology Major Business
Table 32. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 33. Guangdong Wens Dahuanong Biotechnology Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Guangdong Wens Dahuanong Biotechnology Recent Developments/Updates
Table 35. Guangdong Winsun Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guangdong Winsun Bio-Pharmaceutical Major Business
Table 37. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 38. Guangdong Winsun Bio-Pharmaceutical Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Guangdong Winsun Bio-Pharmaceutical Recent Developments/Updates
Table 40. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Manufacturing Base and Competitors
Table 41. Harbin Pharmaceutical Group Bio-vaccine Major Business
Table 42. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 43. Harbin Pharmaceutical Group Bio-vaccine Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Harbin Pharmaceutical Group Bio-vaccine Recent Developments/Updates
Table 45. Wuhan Zhongbo Biotech Basic Information, Manufacturing Base and Competitors
Table 46. Wuhan Zhongbo Biotech Major Business
Table 47. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 48. Wuhan Zhongbo Biotech Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. Wuhan Zhongbo Biotech Recent Developments/Updates
Table 50. China Animal Husbandry Industry Basic Information, Manufacturing Base and Competitors
Table 51. China Animal Husbandry Industry Major Business
Table 52. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Product and Services
Table 53. China Animal Husbandry Industry Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. China Animal Husbandry Industry Recent Developments/Updates
Table 55. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 56. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 57. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 58. Market Position of Manufacturers in Swine Mycoplasma Hyopneumoniae Live Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 59. Head Office and Swine Mycoplasma Hyopneumoniae Live Vaccine Production Site of Key Manufacturer
Table 60. Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Type Footprint
Table 61. Swine Mycoplasma Hyopneumoniae Live Vaccine Market: Company Product Application Footprint
Table 62. Swine Mycoplasma Hyopneumoniae Live Vaccine New Market Entrants and Barriers to Market Entry
Table 63. Swine Mycoplasma Hyopneumoniae Live Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 65. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 66. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 67. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 68. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 69. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 70. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 71. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 72. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 73. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 74. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 75. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 77. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 78. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 79. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 80. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 81. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 82. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 83. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 84. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 85. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 86. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 87. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 88. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 89. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 90. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 91. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 94. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 95. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 96. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 97. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 98. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 99. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 100. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 101. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 102. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 103. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 104. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 105. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 106. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 107. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 108. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 109. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 110. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 111. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 112. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 113. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 114. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 116. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 117. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 118. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 119. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 120. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 121. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 122. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 123. Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Material
Table 124. Key Manufacturers of Swine Mycoplasma Hyopneumoniae Live Vaccine Raw Materials
Table 125. Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Distributors
Table 126. Swine Mycoplasma Hyopneumoniae Live Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Swine Mycoplasma Hyopneumoniae Live Vaccine Picture
Figure 2. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type in 2025
Figure 4. Strain 168 Live Vaccine Examples
Figure 5. Strain RM48 Live Vaccine Examples
Figure 6. Others Examples
Figure 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route in 2025
Figure 9. Intrapulmonary Injection Examples
Figure 10. Intrathoracic Injection Examples
Figure 11. Others Examples
Figure 12. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Pig Farming Groups Examples
Figure 20. Breeding Pig Farms Examples
Figure 21. Animal Health Service Providers Examples
Figure 22. Others Examples
Figure 23. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Swine Mycoplasma Hyopneumoniae Live Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Drivers
Figure 86. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Restraints
Figure 87. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 91. Swine Mycoplasma Hyopneumoniae Live Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
Figure 1. Swine Mycoplasma Hyopneumoniae Live Vaccine Picture
Figure 2. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Type in 2025
Figure 4. Strain 168 Live Vaccine Examples
Figure 5. Strain RM48 Live Vaccine Examples
Figure 6. Others Examples
Figure 7. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Administration Route in 2025
Figure 9. Intrapulmonary Injection Examples
Figure 10. Intrathoracic Injection Examples
Figure 11. Others Examples
Figure 12. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Pig Farming Groups Examples
Figure 20. Breeding Pig Farms Examples
Figure 21. Animal Health Service Providers Examples
Figure 22. Others Examples
Figure 23. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Swine Mycoplasma Hyopneumoniae Live Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Swine Mycoplasma Hyopneumoniae Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Swine Mycoplasma Hyopneumoniae Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Swine Mycoplasma Hyopneumoniae Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Drivers
Figure 86. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Restraints
Figure 87. Swine Mycoplasma Hyopneumoniae Live Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Live Vaccine
Figure 91. Swine Mycoplasma Hyopneumoniae Live Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
